Welcome to our dedicated page for Boston Scien Cp news (Ticker: BSX), a resource for investors and traders seeking the latest updates and insights on Boston Scien Cp stock.
Boston Scientific Corporation (NYSE: BSX) is a global medical technology company whose news flow reflects activity across cardiovascular, neuromodulation, urology, endoscopy and other therapeutic areas. Company announcements frequently describe new agreements to acquire medical technology firms, clinical and regulatory milestones for key product platforms, and detailed quarterly financial results.
Recent news includes a definitive agreement to acquire Penumbra, Inc. in a cash and stock transaction. Penumbra has developed mechanical thrombectomy and neurovascular devices to treat conditions such as pulmonary embolism, stroke, deep vein thrombosis, acute limb ischemia, heart attack and aneurysms, with products like the Lightning Bolt and Lightning Flash computer assisted vacuum thrombectomy systems and peripheral embolization technologies. Boston Scientific has also announced an agreement to acquire Valencia Technologies Corporation, adding the eCoin implantable tibial nerve stimulation system for urge urinary incontinence, and an agreement to acquire Nalu Medical, Inc., developer of the Nalu Neurostimulation System for peripheral nerve stimulation in chronic pain.
In addition to acquisition news, Boston Scientific regularly issues earnings releases detailing net sales by business and region, growth rates on reported, operational and organic bases, and commentary on segment performance in MedSurg and Cardiovascular. These releases often highlight regulatory approvals, such as expanded labeling for the FARAPULSE Pulsed Field Ablation System or CE marks for devices like the WATCHMAN FLX Pro Left Atrial Appendage Closure Device, as well as clinical study results, including long-term data from deep brain stimulation trials.
Investors and observers following BSX news can also expect updates on investor conferences, investor day events, and governance matters disclosed through press releases and Form 8-K filings. This page aggregates such coverage, offering a centralized view of Boston Scientific’s strategic transactions, product developments, financial updates and corporate announcements over time.
Boston Scientific (NYSE:BSX) has received FDA approval for expanded labeling of its FARAPULSE™ Pulsed Field Ablation (PFA) System to treat persistent atrial fibrillation (AF). The system, which delivers pulsed field energy through a catheter to ablate heart tissue, demonstrated strong clinical results in the ADVANTAGE AF trial with a 85.3% symptomatic AF recurrence-free rate.
The trial, involving 260 patients across 43 global sites, showed no major complications and an improved success rate of 91.4% among experienced physicians. Boston Scientific expects CE mark approval and regulatory clearances in Japan and China soon, while also initiating the ReMATCH IDE trial to study the system's effectiveness in approximately 375 patients across 40 centers in the U.S. and Asia.
Boston Scientific (NYSE:BSX) has scheduled a conference call to discuss its second quarter 2025 financial results and business highlights. The call will take place on July 23, 2025, at 8:00 a.m. ET, featuring Chairman and CEO Mike Mahoney and CFO Jon Monson.
The company will release its Q2 2025 financial results prior to the conference call. Investors can access both the live webcast and replay through the company's investor relations website, with the replay becoming available approximately one hour after the event concludes.
Boston Scientific (NYSE: BSX) has announced its participation in two major investor conferences in May 2025. At the Bank of America's 2025 Health Care Conference on May 13, Dan Brennan (EVP & CFO) and Joe Fitzgerald (EVP & Group President, Cardiology) will engage in a 30-minute Q&A session starting at 8:00 a.m. PT. Later, on May 28, at Bernstein's 41st Annual Strategic Decisions Conference, Chairman & CEO Mike Mahoney and Dr. Ken Stein (SVP & Global Chief Medical Officer) will participate in a 50-minute Q&A session beginning at 8:00 a.m. ET. Both events will be available via live webcast and replay on the company's investor relations website.
Boston Scientific (NYSE: BSX) announced positive 12-month results from the second phase of the ADVANTAGE AF clinical trial for their FARAPULSE™ Pulsed Field Ablation System. The study evaluated the treatment of persistent atrial fibrillation using the FARAWAVE™ PFA Catheter and FARAPOINT™ PFA Catheter.
Key findings include:
- 73.4% freedom from AF, AFL and atrial tachycardia, exceeding the 40% performance goal
- 2.4% safety event rate with no reports of major complications
- 81% freedom from symptomatic documented AF recurrence
- 96.4% of patients treated with FARAPOINT PFA Catheter showed no AFL recurrence
The trial involved 255 patients across 29 U.S. sites. Boston Scientific expects FDA approval to expand labeling for persistent AF and regulatory approvals for the FARAPOINT PFA Catheter in H2 2025.
Boston Scientific (NYSE: BSX) announced that CFO Dan Brennan will retire after nearly 30 years with the company. Brennan will step down as CFO at the end of June 2025 and remain as senior advisor through early October 2025.
Jon Monson, currently senior vice president of Investor Relations, will succeed Brennan as executive vice president and CFO effective June 30, 2025. Monson brings over 25 years of experience at Boston Scientific and will oversee global controllership, internal audit, corporate finance, treasury, corporate tax, investor relations and corporate business development.
Monson previously served as global controller and chief accounting officer for five years and vice president and controller of the company's Urology business for four years. He played a key role in navigating the company through the 2020 pandemic as global controller.
Boston Scientific (NYSE: BSX) reported strong Q1 2025 financial results with net sales of $4.663 billion, marking a 20.9% reported growth and 18.2% organic growth year-over-year. The company achieved GAAP EPS of $0.45 and adjusted EPS of $0.75, surpassing guidance.
Key segment performance showed remarkable growth, with Cardiovascular segment up 26.2% and MedSurg up 11.7%. Regional performance was led by the U.S. with 31.1% growth. The company completed strategic acquisitions including Bolt Medical and announced plans to acquire SoniVie
Looking ahead, Boston Scientific projects full-year 2025 net sales growth of 15-17% on a reported basis and 12-14% organically, with adjusted EPS guidance of $2.87-2.94. For Q2 2025, the company expects reported sales growth of 17.5-19.5% and organic growth of 13-15%.
Nalu Medical has appointed Raymond W. Cohen as chairman of its board of directors. Cohen previously served as CEO and board member of Axonics, a medical device company he co-founded in 2013 and took public in 2018. Under his leadership, Axonics achieved recognition as the fastest-growing company in the Americas by Deloitte and Financial Times in 2021 and 2022.
Cohen recently oversaw Axonics' $3.7 billion sale to Boston Scientific (NYSE: BSX) in November 2024. He also served as chairman of SoniVie, which was sold to BSX for $600 million in March 2025. Currently, he serves on the board of Kestra Medical Technologies (Nasdaq: KMTS), which recently completed a $232 million IPO.
Boston Scientific (NYSE: BSX) has scheduled a conference call to discuss its first quarter 2025 financial results and business highlights on Wednesday, April 23, 2025, at 8:00 a.m. ET. The company will release its Q1 financial results prior to the call on the same day.
The conference call will be led by Mike Mahoney, chairman and CEO, alongside Dan Brennan, executive vice president and CFO. Investors and interested parties can access the live webcast and replay through the company's investor relations website.
Boston Scientific (NYSE: BSX) has announced an agreement to acquire SoniVie , developer of the investigational TIVUS™ Intravascular Ultrasound System for treating hypertension through renal denervation (RDN). The acquisition expands BSX's Interventional Cardiology Therapies portfolio.
The transaction includes an upfront payment of approximately $360 million for the 90% stake not currently owned by BSX (which holds ~10% equity), plus up to $180 million in regulatory milestone payments. The TIVUS system uses ultrasound energy to denervate renal arteries, potentially offering deeper tissue penetration and faster procedures compared to radiofrequency alternatives.
The deal is expected to close in first half 2025, with slight dilution to adjusted EPS in 2025, which BSX plans to offset through internal cost efficiencies. SoniVie recently reported positive efficacy data from an IDE pilot trial and has initiated the THRIVE global IDE pivotal trial.
FAQ
What is the current stock price of Boston Scien Cp (BSX)?
What is the market cap of Boston Scien Cp (BSX)?
